Cite
HARVARD Citation
Stenzl, A. et al. (2022). The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 82 (13), pp. 1237-1247. [Online].